Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy
Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy. Funds will support the marketing authorization review process for male patients with AMN and launch preparations in Europe, as well as activities required for US approval pathway Proceeds will also cover activities for extension of indication to entire […]
Read Post
Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease
Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease – First Time Patients Will be Treated with the Company’s Orally Available Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium – NEW YORK, May 5, 2022 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a […]
Read Post
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies MUNICH, GERMANY, May 3, 2022 – Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing […]
Read Post
Cellaïon announces update to its Board of Directors: Dr. Fouzia LAGHRISSI-THODE joins the biotech as Member of the Board
Cellaïon announces update to its Board of Directors: Dr. Fouzia LAGHRISSI-THODE joins the biotech as Member of the Board Mont-Saint-Guibert, Belgium, 29/03/2022: Cellaïon a Walloon biotechnology company developing Life saving advanced therapies to repair tissues and regenerate the liver today announced the following change to its Board of Directors. Highly experienced, Dr. Laghrissi-Thode has over […]
Read Post
Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain
Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain — Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects […]
Read Post
Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity
– Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3 Dose Selection – – Completed Enrollment of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis; Top-Line Data Expected in June of 2022 […]
Read Post
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients • Financing with equal contribution by an international investor syndicate comprising of Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures • Funds will accelerate development of first-in-class targeted thrombolytic treatment into clinical development Utrecht, […]
Read Post
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
Partnership Press Release eTheRNA Announces Research Agreement with Merck to access mRNA technologies Niel, Belgium | 03 February 2022 | eTheRNA immunotherapies NV (“eTheRNA”) is pleased to announce the start of a strategic partnership with Merck with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA’s proprietary mRNA design expertise […]
Read Post
Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer.
January 12th, 2022 – Epics Therapeutics S.A., a private drug development company, announced today the initiation of a First-in-Human, double-blind, placebo-controlled, single and multiple ascending dose study of EP282 to evaluate oral pharmacokinetics, pharmacodynamics, safety and tolerability in healthy male volunteers. Specific biomarkers will also be monitored to evaluate drug-target engagement at different dose levels. […]
Read Post
Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform
Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform Ghent, Belgium – December 15, 2021 – Confo Therapeutics a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert […]
Read Post
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
– Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments in Healthy Human Subjects – – Single Daily Dosing up to 400 mg and Multiple Daily Dosing of 300 mg were Found to Be Safe and Well-Tolerated in Healthy Human Subjects (With No Maximum Tolerated Dose Established) […]
Read Post
Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer
NEW YORK, Dec. 9, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in its open-label phase 1 trial of IMU-935, a highly potent and selective inverse agonist of the transcription factor […]
Read Post
ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors
ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space Barcelona, Spain, 2 December 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat […]
Read Post
Confo Therapeutics Enters Collaborative Agreement with Regeneron
Confo Therapeutics Enters Collaborative Agreement with Regeneron — Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery — Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which […]
Read Post
Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis
NEW YORK, Nov. 18, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the first patient enrolled in its phase 3 ENSURE program of lead asset, vidofludimus calcium (IMU-838), the company’s selective oral DHODH inhibitor, in patients with […]
Read Post
Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity
– Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis – – Initiated Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, Intended to Run Concurrently With and to Complement the Company’s Phase 3 ENSURE Program in Relapsing Multiple Sclerosis – – $110.4 Million in Cash and Cash Equivalents as of September 30, […]
Read Post
Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021
Presentation highlights reduction in cerebral lesion progression and the risk of developing cerebral ALD in AMN patients based on MRI and plasma biomarker data. Mataró, Barcelona, Spain, November 3, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, […]
Read Post
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors New investment to fuel continued growth of 3M³ platform for the development of products in tissue reconstruction and oncology Mont Saint-Guibert, Belgium – October 28, 2021 – Novadip Biosciences (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired […]
Read Post
Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis
– Top-Line Data Expected in the Second Quarter of 2022 – NEW YORK, Oct. 28, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the final patient has been enrolled and randomized in its phase […]
Read Post
Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers
Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has completed a €40M ($46.4M) Series A financing. The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund. Fund+, Bioqube Ventures and […]
Read Post
ONA Therapeutics Strengthens Scientific Leadership Team
ONA Therapeutics Strengthens Scientific Leadership Team Industry veteran in oncology antibody discovery & development Dr Haijun Sun appointed Chief Scientific Officer Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development Barcelona, Spain, 21 October 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and […]
Read Post
Fund+ on LN24
Very proud of FundPlus on LN24 in #successstories, #lifesciences #biotechs #investmentopportunities #clinicaldevelopment #financing (Fund+ as of 21min30sec in the #video) #LN24 #pierrehermant https://www.ln24.be/2021-10-18/success-stories-une-therapie-unique-de-neurostimulation-du-nerf-et-la-bourse-et-les
Read Post
Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
NEW YORK, Oct. 14, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today. In this newly created role, Mr. Walsh will be responsible for business development, including […]
Read Post
Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board
Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board – Dr. Olivier Danos PhD, is currently Chief Scientific Officer of RegenxBio – Frederic Chereau MBA, is currently President and CEO of LogicBio Paris, France, 12th October 2021 – Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene […]
Read Post
Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis
NEW YORK, Sept. 30, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in its phase 2 CALLIPER trial of lead asset IMU-838, the company’s selective oral DHODH inhibitor, in patients with progressive […]
Read Post